59
Participants
Start Date
May 20, 2022
Primary Completion Date
January 11, 2023
Study Completion Date
December 5, 2023
TQC3721 suspension for inhalation
TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
TQC3721 suspension placebo for inhalation
TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
The First Affiliated Hospital of China Medical University, Shenyang
The First Hospital of Jilin University, Changchun
The Fourth Affiliated Hospital of Harbin Medical University, Harbin
The Affiliated Hospital of Xuzhou Medical University, Xuzhou
Northern Jiangsu People's Hospital, Yangzhou
The First Affiliated Hospital of Nanchang University, Nanchang
The First Affiliated Hospital of Chongqing Medical University, Chongqing
The Affiliated Hospital of Guangdong Medical University, Zhanjiang
West China Hospital of Sichuan University, Chengdu
Mianyang Central Hospital, Mianyang
Gansu Provincial Hospital, Lanzhou
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY